Rya Naik* and Akash Shetty
Objective, The objective of this study was to evaluate the dengue burden in India and to present a review of the vaccine, DENGVAXIA®.
Overview, Dengue fever is a mosquito-borne viral infection that has spread quickly through all regions in recent years. Female mosquitoes, primarily Aedes aegypti and, to a lesser degree, Aedes albopictus, transmit the dengue virus. Dengue fever affects nearly 2.5 billion people worldwide, with an estimated 100 million new cases per year. Dengue fever claimed the lives of 245 people in India in 2016, with 1,29,166 cases recorded. There were 132 dengue deaths and 1,36,422 cases recorded from January to November of 2019.Sanofi's Dengvaxia® was approved by the Food and Drug Administration (FDA) in 2015. Following this, long- term follow-up of participants in the Sanofi phase III efficacy trial revealed significant safety issues. In this article, we aim to provide information about the dengue virus's prevalence in India, as well as a review of Dengvaxia® also describing it results and safety along with other vaccines and its approval in the listed country. Dengvaxia® is indicated for the prevention of dengue fever caused by serotypes 1-4 of the dengue viruses. Dengvaxia® is approved for use in people aged 9-16 who have had a previous dengue infection that has been confirmed in a laboratory and who lives in an endemic area.
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu